Introduction to Richard Francis, Chief Executive of Purespring Therapeutics

Richard Francis discusses why he has taken on the role of CEO at PureSpring Therapeutics, the importance of Syncona’s role (and expertise in the AAV gene therapy field), and the unique opportunity PureSpring has to make a difference to millions of people as it seeks to develop transformational treatments for patients in areas of high unmet need.

Back to News and insights